Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 4101 - 4125 of 8039 in total
Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.
Investigational
Matched Description: … Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of
XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.
Investigational
Matched Description: … XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. …
Progabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. In clinical trials, progabide has been investigated for Parkinson's disease, schizophrenia, clinical depression and anxiety disorder; its therapeutic effectiveness in these...
Experimental
Matched Description: … It is commonly used in the treatment of epilepsy. ... Progabide is an analog and prodrug of gamma-aminobutyric acid. …
Tesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast cancer.
Investigational
Matched Description: … Tesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected …
G17DT Immunogen is a vaccine that neutralizes gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract. It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine. It is also in a phase II/III trial for...
Investigational
Matched Description: … of cancers of the gastrointestinal tract. ... G17DT Immunogen is a vaccine that neutralizes gastrin-17, a hormone required for the growth of a number …
Canfosfamide is an active agent in chemotherapy-resistant ovarian cancer.
Investigational
Aplidine is a peptide found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers. The specific marine organism is Aplidium albicans. Aplidine is also of interest as a potential treatment for some leukemias.
Investigational
Matched Description: … Aplidine is also of interest as a potential treatment for some leukemias. …
CG7870 is an oncolytic virus therapy for prostate cancer. It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
Investigational
Matched Description: … a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of
1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC class II-positive tumor cells, which include...
Investigational
Matched Description: … The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies …
ZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles. It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells.
Investigational
Matched Description: … ZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles …
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of episodic, progressive heterotropic ossification. FOP is characterized by episodic inflammatory episodes, which may be precipitated by trauma, including immunizations and minor tissue damage, which usually result in ossification of the lesion. Patients experience abnormal cartilage formation, growth plate dysplasia,...
Investigational
Matched Description: … Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of episodic, progressive ... [A242297, A242307] The discovery of an activating mutation in the ACVR1 receptor that renders it responsive ... precipitated by trauma, including immunizations and minor tissue damage, which usually result in ossification of
Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss was banned in the United States in 2004 due to the risk for adverse effects and a lack of evidence for clinical effectiveness....
Nutraceutical
Matched Description: … The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss ... was banned in the United States in 2004 due to the risk for adverse effects and a lack of evidence for …
Idronoxil is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called signal transduction inhibitors.
Investigational
Matched Description: … Idronoxil is a substance that is being studied in the treatment of cancer. ... It belongs to the family of drugs called signal transduction inhibitors. …
NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.
Investigational
NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation or chemotherapy. Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.
Investigational
Matched Description: … Phase I/II trials commenced in March 2001 and were ongoing as of June 2003. ... liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of
SP1049C is a novel anthracycline chemotherapeutic agent containing doxorubicin and two nonionic pluronic block copolymers. It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review. Preliminary data, in its first clinically tested indication,...
Investigational
Matched Description: … [A260416] It is designed to overcome drug resistance in a number of cancers. ... clinically tested indication, shows that SP1049C is active in Stage IV non-resectable adenocarcinoma of
IGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.
Investigational
Cinolazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. It is not approved in Canada or America.
Experimental
Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis . The drug made it to phase III trials before abandoned due to increased stroke.
Investigational
Matched Description: … Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment …
SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 (V1b) receptor subtype. It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).
Investigational
Matched Description: … It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion ... of anti-diuretic hormone (SIADH). ... SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 ( …
M40403 is a low molecular weight, synthetic manganese containing superoxide dismutase mimetic (SODm) that selectively removes superoxide anion.
Investigational
Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain . The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class...
Investigational
Matched Description: … The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique ... of chronic lower back pain [L3263] ... developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of
Roxatidine acetate is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.
Experimental
An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
Investigational
Matched Description: … It is used in cell biological experiments as an inhibitor of phospholipase A2. ... It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. …
Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of typhoid fever. The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of S. typhi. It is being developed by AVANT Immunotherapeutics, Inc.
Investigational
Matched Description: … vaccine designed to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of ... developed using genetic techniques to delete specific genes known to be essential to the virulence of
Displaying drugs 4101 - 4125 of 8039 in total